# Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

> **NCT00265395** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1428 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)
- **DRUG:** Combination of pegylated interferon alfa-2b and ribavirin

## Key facts

- **NCT ID:** NCT00265395
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 1428 (ACTUAL)
- **Last updated:** 2017-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00265395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00265395, "Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00265395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*